Stephanie Y. Brule

Sep 5, 2023 | acsjournals.onlinelibrary.wiley.com | Corey Tsang |Jessica Robinson |Paul Wheatley-Price |Stephanie Y. Brule

Paclitaxel has a risk of infusion-related reactions (IRRs) and despite no prospective evidence, is often given with premedication including a corticosteroid, H1 antagonist, and H2 antagonist (H2RA). Backorders impacted the supply of intravenous H2RAs at our center, and it was removed as routine premedication. The authors compared the incidence of IRR in patients treated without H2RA to patients receiving standard H2RA premedication.